European journal of nuclear medicine and molecular imaging

publication venue for

Correction to: Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging. 2024
Correction to: [⁸⁹Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. 2022
⁸⁹Zr-immunoPET-guided selection of a CD33xIL15 fusion protein optimized for antitumor immune cell activation and in vivo tumour retention in acute myeloid leukaemia. 2024
Examination of the PET in vivo generator ¹³⁴Ce as a theranostic match for ²²⁵Ac. 2024
Quantitative analysis of myocardial blood flow in surgically revascularized and not revascularized myocardial segments. A pilot PET study. 2023
Joint EANM/SNMMI procedure guideline for the use of ¹⁷⁷Lu-labeled PSMA-targeted radioligand-therapy (¹⁷⁷Lu-PSMA-RLT). 2023
PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0. 2023
The potential of a medium-cost long axial FOV PET system for nuclear medicine departments. 2022
Carbonic anhydrase IX stratifies patient prognosis and identifies nodal status in animal models of nasopharyngeal carcinoma using a targeted imaging strategy.. 49. 2022
[⁸⁹Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma.. 49. 2021
Prognostic value of [¹⁸F]FDG PET/CT in patients with CNS lymphoma receiving ibrutinib-based therapies. 2021
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals.. 48. 2021
Supervised machine learning enables non-invasive lesion characterization in primary prostate cancer with [⁶⁸Ga]Ga-PSMA-11 PET/MRI.. 48. 2020
Prediction of response and survival after standardized treatment with 7400 MBq ¹⁷⁷Lu-PSMA-617 every 4 weeks in patients with metastatic castration-resistant prostate cancer.. 48. 2020
IntraOmmaya compartmental radioimmunotherapy using ¹³¹I-omburtamab-pharmacokinetic modeling to optimize therapeutic index.. 48. 2020
Comparison of ⁶⁸Ga-DOTA-JR11 PET/CT with dosimetric ¹⁷⁷Lu-satoreotide tetraxetan (¹⁷⁷Lu-DOTA-JR11) SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy.. 47. 2020
¹⁸F-Fluorocholine PET uptake correlates with pathologic evidence of recurrent tumor after stereotactic radiosurgery for brain metastases.. 47. 2019
Clinical outcome of standardized ¹⁷⁷Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7400 MBq every 4 weeks.. 47. 2019
Prospective evaluation of the performance of [⁶⁸Ga]Ga-PSMA-11 PET/CT(MRI) for lymph node staging in patients undergoing superextended salvage lymph node dissection after radical prostatectomy.. 46. 2019
Response assessment using ⁶⁸Ga-PSMA ligand PET in patients undergoing ¹⁷⁷Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer.. 46. 2018
Prognostic value of baseline metabolic tumor volume measured on ¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy.. 46. 2018
Biodistribution and radiation dose estimates for ⁶⁸Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors.. 46. 2018
Quantitative evaluation of tau PET tracers ¹⁸F-THK5351 and ¹⁸F-AV-1451 in Alzheimer's disease with standardized uptake value peak-alignment (SUVP) normalization.. 45. 2018
Trifunctional PSMA-targeting constructs for prostate cancer with unprecedented localization to LNCaP tumors.. 45. 2018
Tumour functional sphericity from PET images: prognostic value in NSCLC and impact of delineation method.. 45. 2017
⁶⁸Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.. 45. 2017
⁶⁸Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0.. 44. 2017
Synthesis and pre-clinical evaluation of a new class of high-affinity ¹⁸F-labeled PSMA ligands for detection of prostate cancer by PET imaging.. 44. 2016
Nuclear cardiology practice and associated radiation doses in Europe: results of the IAEA Nuclear Cardiology Protocols Study (INCAPS) for the 27 European countries.. 43. 2015
Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.. 43. 2015
PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.. 42. 2015
Appearance of untreated bone metastases from breast cancer on FDG PET/CT: importance of histologic subtype.. 42. 2015
Reduced retention of Pittsburgh compound B in white matter lesions.. 42. 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer.. 41. 2014
18F-FDG PET of the hands with a dedicated high-resolution PEM system (arthro-PET): correlation with PET/CT, radiography and clinical parameters.. 41. 2014
Performance of intra-procedural 18-fluorodeoxyglucose PET/CT-guided biopsies for lesions suspected of malignancy but poorly visualized with other modalities.. 41. 2014
Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcinoma.. 41. 2014
Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter.. 41. 2013
Absolute myocardial flow quantification with (82)Rb PET/CT: comparison of different software packages and methods.. 41. 2013
Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.. 40. 2013
The impact of systemic chemotherapy on testicular FDG activity in young men with Hodgkin's lymphoma.. 40. 2013
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid.. 38. 2010
Detection of hypoxia in microscopic tumors using 131I-labeled iodo-azomycin galactopyranoside (131I-IAZGP) digital autoradiography.. 37. 2009
PET imaging of HSV1-tk mutants with acquired specificity toward pyrimidine- and acycloguanosine-based radiotracers.. 36. 2009
Chronic thyroiditis in patients with advanced breast carcinoma: metabolic and morphologic changes on PET-CT.. 36. 2009
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.. 36. 2009
Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.. 35. 2008
Quantitative PET imaging of Met-expressing human cancer xenografts with 89Zr-labelled monoclonal antibody DN30.. 35. 2008
Tumor hypoxia imaging in orthotopic liver tumors and peritoneal metastasis: a comparative study featuring dynamic 18F-MISO and 124I-IAZG PET in the same study cohort.. 35. 2007
Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease.. 34. 2007
Quantification of Parkinson's disease-related network expression with ECD SPECT.. 34. 2006
Human radiation dosimetry of [11C]MeAIB, a new tracer for imaging of system A amino acid transport.. 33. 2006
[131I]FIAU labeling of genetically transduced, tumor-reactive lymphocytes: cell-level dosimetry and dose-dependent toxicity.. 33. 2006
Visual rating of medial temporal lobe metabolism in mild cognitive impairment and Alzheimer's disease using FDG-PET.. 33. 2005
Respiration artifacts in whole-body (18)F-FDG PET/CT studies with combined PET/CT tomographs employing spiral CT technology with 1 to 16 detector rows.. 32. 2005
Dosimetry of 60/61/62/64Cu-ATSM: a hypoxia imaging agent for PET.. 32. 2005
A preclinical model for noninvasive imaging of hypoxia-induced gene expression; comparison with an exogenous marker of tumor hypoxia.. 31. 2004
Brain perfusion abnormalities in patients with euthyroid autoimmune thyroiditis.. 31. 2004
A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging.. 31. 2004
Iodine-124-labeled iodo-azomycin-galactoside imaging of tumor hypoxia in mice with serial microPET scanning.. 31. 2003
[Tc(CO)(3)](+) chemistry: a promising new concept for SPECT? Against.. 30. 2003
In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.. 30. 2003
Imaging of dihydrofolate reductase fusion gene expression in xenografts of human liver metastases of colorectal cancer in living rats.. 30. 2003
Prognostic value of [18F]FDG-PET imaging in small cell lung cancer.. 30. 2002
Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans.. 30. 2002
Whole-body skeletal imaging in mice utilizing microPET: optimization of reproducibility and applications in animal models of bone disease.. 29. 2002
Amino acid uptake in the skeletal muscle measured using [11C]methylaminoisobutyrate (MEAIB) and PET.. 29. 2002
Standardized uptake value in pediatric patients: an investigation to determine the optimum measurement parameter.. 29. 2001
PSMA PET/CT cost-effectiveness analysis in the USA: a response to a published commentary. 2023
Toward individualized dosimetry for radiopharmaceutical therapy in day-to-day clinical practice of nuclear oncology: overcoming heterogeneity of radiation-absorbed dose to tumor and critical organs. 2023
Doctor, what does my future hold? The prognostic value of FDG-PET in solid tumours. 2010
Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. 2005
PET/CT: a new imaging technology in nuclear medicine. 2003
Current clinical applications of Cerenkov luminescence for intraoperative molecular imaging. 2024
Dynamic whole-body PET imaging: principles, potentials and applications. 2018
From PET detectors to PET scanners. 2003

VIVO Weill Cornell Medical College

European journal of nuclear medicine and molecular imaging Journal

Overview

publication venue for

Identity

ISO Abbreviation

Linking ISSN

International Standard Serial Number (ISSN)

Electronic International Standard Serial Number (EISSN)